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Highlights: 
 Exosomes populate the cerebrospinal fluid of preterm infants with post-
haemorrhagic hydrocephalus 
 Exosomes found after intraventricular hemorrhage are from serum and brain 
 Micro-RNAs isolated from the exosomal fraction relate to development and 
disease 
 
Abstract 
Background 
Preterm infants are at risk of germinal matrix haemorrhage-intraventricular 
haemorrhage (GMH-IVH) which leads to post-haemorrhagic hydrocephalus (PHH) in 
30% of infants; this is associated with moderate-severe neurodevelopmental 
impairment and confers significant risk of cerebral palsy. There are however no 
predictive indicators of the severity or long-term outcome after GMH-IVH.  In recent 
years, endosome-derived extracellular vesicles (EVs) or exosomes have been isolated 
from biofluids and shown to mediate intercellular communication via selective 
enrichment in proteins and micro-RNAs.   
Methods 
This study aimed to isolate and characterise EVs from the cerebrospinal fluid (CSF) of 
3 preterm infants with PHH using nanoparticle tracking analysis (NTA), transmission 
electron microscopy (TEM) with immunogold protein labelling, and micro-RNA 
analysis. 
Results 
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NTA of unaltered CSF revealed a heterogeneous and dynamic population of EVs.  
Exosomal-sized EVs were isolated by differential ultracentrifugation and TEM 
confirmed the presence of CD63+ and CD81+ exosomes. The micro-RNAs miR-9, miR-
17, miR-26a, miR-124 and miR-1911 were detected within the exosome-enriched 
fraction and profiled over time. 
Conclusion 
This is the first reported characterisation of exosomes from the CSF of preterm 
infants with post-haemorrhagic hydrocephalus.  
 
Keywords: Exosome; Preterm infant; Cerebrospinal fluid; Intraventricular 
hemorrhage; Cerebral palsy; Micro RNA 
 
1 Background 
Preterm infants (<32 weeks gestational age) are at risk of a serious brain injury, 
called germinal matrix haemorrhage - intraventricular haemorrhage (GMH-IVH). 
GMH-IVH most commonly occurs in the first 48h after birth1 and is thought to arise 
from rupture of the capillaries of the subependymal germinal matrix2. Despite 
improved neonatal care leading to better survival, the incidence of GMH-IVH has 
remained static3. Post-haemorrhagic hydrocephalus (PHH) is a serious complication 
of GMH-IVH and aspiration from a ventricular access device is used to relieve the 
excess cerebrospinal fluid (CSF) from the ventricles. GMH-IVH can lead to many 
moderate to serious comorbidities, such as cerebral palsy4. To date we lack predictive 
indicators to identify the level of the damage or the long-term outcomes of GMH-IVH. 
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However, in recent years, exosomes isolated from body fluids have emerged as 
reservoirs of sensitive biomarkers.   
Exosomes are spherical cell-derived vesicles between 30-100nm in diameter5. The 
earliest evidence of exosomes came in the 1980s when the vesicular release of the 
intact transferrin receptor from maturing reticulocytes was observed in vitro6. 
Exosomes are produced by almost all cell types including neurons, microglia, and 
dendritic cells in the CNS7. Exosomes fall under the category of extracellular vesicles 
(EV) which also includes microvesicles (also known as ectosomes) and apoptotic 
bodies7,8. Their key difference is their mode of biogenesis and several features are 
used to identify them: Exosomes are actively released by cells as a product of the 
endocytic pathway and are typically considered to be 30-100nm in diameter; 
microvesicles are a product of, probably passive, plasma membrane budding and 
range from 50-1000nm; while apoptotic bodies, a product of apoptosis, are typically 
50-5000nm5,6,8,9. Aside from size, exosomes differ in their selective enrichment in 
certain proteins including tetraspanins CD63, CD81, and CD910-13.  
Interest in exosomes has grown rapidly and they are now recognised as sophisticated 
means of long and short distance intercellular communication9. Systemic 
inflammation has been shown to increase the release of extracellular vesicles by the 
choroid plexus epithelium. These vesicles contain pro-inflammatory factors -
including microRNAs- that directly cause the activation of astrocytes and microglia in 
the brain parenchyma14.  Exosomes in the embryonic CSF have also been shown to 
modulate IGF signalling and promote Neural Stem Cell proliferation (NSC)15. 
Exosomes have been proposed as promising non-invasive diagnostic tools for 
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cancer16, kidney diseases17 and neurodegeneration18,19 but have not been explored in 
neonatal development and GMH-IVH/PHH.  
 
2 Methods 
2.1 Diagnosis of PHH and CSF collection 
CSF was collected from preterm infants born at less than 32 weeks gestation treated 
for evolving posthaemorrhagic hydrocephalus (PHH) admitted to the regional 
Neonatal Intensive Care Unit at Southmead Hospital in Bristol, United Kingdom. 
Intraventricular haemorrhage (IVH) was diagnosed on routine trans-fontanel cranial 
ultrasound studies (CUSS). Subsequent CUSS were performed 1-3 times a week in 
order to follow progression of GMH-IVH and development of PHH. The diagnosis and 
treatment of PHH was indicated by the ultrasound measurement of ventricular index 
(VI) and anterior horn width (AHW) according to Levene & Sartre20. External CSF 
drainage was indicated by VI and AHW exceeding 97th percentile and initially 
undertaken via lumbar puncture before insertion of a ventricular access device (VAD) 
if ventricular enlargement persisted above the 97th percentile (Department of 
Paediatric Neurosurgery, Bristol Royal Hospital for Children, Bristol, United 
Kingdom). 
CSF used in this study was the excess fluid remaining after routine testing of samples 
taken for clinical indications following informed parental consent. Initial sample 
volume was 10mL/kg body weight, the mean volume per sample available for testing 
was 4.4mL. Ethical approval for analysis of the CSF was obtained from NHS Research 
Ethics Committee (REC number: 15-YH-0251). From each patient, CSF was collected 
at different time points. CSF was centrifuged to remove cellular material and the 
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supernatant frozen at -20°C within an hour of collection, with transfer to -80°C as 
soon as practicable. Patients with suspected CNS infection (defined as raised WCC or 
positive bacterial culture in the CSF), known genetic abnormalities, or presenting 
with CNS malformation were excluded from the study. Patients and samples used in 
this study are indicated in Table S1. 
2.2 Nanoparticle Tracking Analysis 
Unprocessed CSF nanoparticle size distribution and concentration was determined 
using the NanoSight NS300 (Malvern, Amesbury, UK). CSF was diluted in distilled 
water (final volume 1ml) to ensure an appropriate concentration of particles 
detectable by the instrument. Each sample was analysed in triplicate using video 
recordings each 3 minutes in duration. 
2.3 Differential ultracentrifugation  
Exosome isolation was based on the method described by Théry et al 21 and took 
place at 4°C unless otherwise stated. CSF was thawed in 1.5ml Eppendorf Tubes, 
vortexed, then centrifuged at 2000g for 10min, then again at 10,000g for 20min to 
pellet dead cells and cell debris. The supernatant was then transferred into 1.5ml 
Beckman Ultracentrifuge Tubes (Beckman Coulter, London, UK) and ultracentrifuged 
in a fixed angle TLA-55 rotor (Beckman Coulter, London) at 100,000g (40,000 rpm) 
for 70min to pellet the exosomes. If a washing step was required, the exosome-
enriched pellet was resuspended in PBS and ultracentrifuged as above. The pellet was 
resuspended in 100μl of filtered PBS and stored at -80°C until further analysis.  
Repeat freeze-thaw cycles (> 2) were avoided. For a flow diagram of this method see 
Figure S1. 
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2.4 exoEasy Maxi Kit extracellular vesicle purification 
CSF was thawed in 1.5ml Eppendorf Tubes and vortexed. All spin columns, collection 
tubes, and reagents were supplied in the exoEasy Maxi kit (Qiagen, Manchester, UK) 
and isolation was performed according to the manufacturer’s instructions. Briefly, 
CSF from each patient was added to Buffer XBP (1:1), mixed thoroughly, and allowed 
to reach room temperature. This was centrifuged through an exoEasy spin column 
(max 16ml/column) at 500g for 1min. Flow-through was discarded and the column 
washed through with 10mL buffer XWP centrifuged at 5,000g for 5min. The flow-
through was discarded and 400μl Buffer XE was added to the spin column, incubated 
at room temperature for 1min, then centrifuged at 500g for 5min, then again with the 
same eluate at 5,000g for 5min (Figure S1) and the final eluate (400μl) was stored at -
80°C until RNA extraction. 
2.5 Transmission electron microscopy  
Negative staining was adapted from a previously described method22.   If immunogold 
labelling did not occur, 2μl of the EV-enriched sample was placed on a carbon-coated 
formvar film on a copper grid (300 mesh) (Agar Scientific, Stansted, UK) and left for 1 
min. For all samples the grid was washed on a droplet of distilled water for 10sec 
prior to incubation in uranyl acetate (3% in dH20) (BDH Industries, Mumbai, India) 
and methyl cellulose (2% in dH20) (Sigma Aldrich) mixed in a ratio of 1:9 for 5min on 
ice. Using a loop to remove excess fluid, the grid was dragged across a Whatman 1 
filter (GE Healthcare, Buckinghamshire, UK) and left to air-dry upright.  
Immunogold labelling was adapted from a previously described method 22. All 
incubations occurred at room temperature unless otherwise stated. Following 
exosome isolation 2μl of sample were placed onto a carbon-coated formvar film on a 
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copper grid (300 mesh) (Agar Scientific, Stansted, UK) and left for 2min. Grids were 
fixed and blocked by incubation for 5min per step on a drop of 1% paraformaldehyde 
(PFA) (Sigma Aldrich, Irvine, UK), then 50nM glycine in PBS (Gibco), followed by 0.1% 
bovine serum albumin (BSA-c) (Aurion, The Netherlands). Grids were then incubated 
with the selected primary antibody: anti-CD63 mAb (100μg/ml) or anti-CD81 mAb 
(200μg/ml) (both diluted 1:50 in 0.1% BSA and both Santa Cruz Biotechnology, 
Heidelberg, Germany) and left for at least 30min. Grids were washed 3 times in 0.1% 
BSA to prevent secondary staining, allowing 5min between washes, then incubated on 
a drop of secondary gold-conjugated goat anti-mouse IgG (Aurion) (6nm) (diluted 
1:20 in 0.1% BSA/PBS) and left for at least 30min. Grids were washed 3 times and 
negatively stained as above.   
All Grids were viewed and photographed using a FEI Tecnai 12 transmission 
electron microscope and images analysed using ImageJ.  
2.6 Exosome size distribution measurements 
15 randomly-taken electron micrographs per sample were analysed in ImageJ. EVs 
were identified as spherical/cup-shaped particles with the presence of a surrounding 
continuous membrane and the Feret’s diameter of each EV was determined.  
2.7 RNA extraction  
Total RNA was extracted from EVs using the mirVana™ miRNA Isolation Kit (Ambion) 
according to the manufacturer’s instructions using reagents included in the kit. 500μl 
lysis/binding solution were added directly to pelleted exosomes to maximise RNA 
yield, then vortexed to lyse the exosomes. miRNA Homogenate Additive was added 
(1/10 the volume of the exosome lysate), vortexed, and incubated on ice for 10min. 
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500μl Acid-Phenol:Chloroform was added and vortexed, then centrifuged at 10,000g 
for 5min at room temperature (Eppendorf centrifuge 5430R). The upper aqueous 
phase was carefully removed and transferred to a fresh 1.5ml Eppendorf tube and x 
1.25 volumes of 100% ethanol (Sigma Aldrich) was added. This mixture was passed 
through a Filter Cartridge by centrifuging at 10,000g for 15sec, and the Filter 
Cartridge washed with 700μl miRNA Wash Solution 1 by centrifuging at 10,000g for 
15sec. This step was repeated twice with 500μl Wash Solution 2/3 with a final spin at 
10,000g for 1min. The contents were eluted by passing 100μl of nuclease-free water 
(pre-heated to 95°C) through the Filter Cartridge and spun at maximum speed for 20-
30sec. The eluate, containing total RNA, was stored at -20°C until further analysis. 
Total RNA concentration was measured using the Nanotube 2000 spectrophotometer 
(Thermo Fisher). 
2.9 Candidate miRNA selection 
miRNAs were selected based on their enrichment in specific fractions of CSF/serum. 
This was based on a recent report by Yagi et al. (2017) who performed next 
generation sequencing of exosomal miRNAs within adult human CSF23.  
2.10 qRT-PCR 
Reverse transcription (RT) and real-time PCR (qPCR) were performed using the 
TaqMan® MicroRNA Assay according to the manufacturer’s instructions (Applied 
Biosystems, ThermoFisher). Single-stranded cDNA was synthesized using miRNA-
specific RT looped-primers (5X). Each 10μl RT reaction contained 6ng/ml total RNA. 
Using the cDNA products from above, qPCR was performed using sequence-specific 
primers and the TaqMan Universal Master Mix II, containing no uracil N-glycosylase 
(UNG) (Applied Biosystems). qPCR was performed in triplicates on a StepOnePlus 
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real-time PCR system (Applied Biosystems) to detect mature miRNA expression. As 
there are no housekeeping RNAs yet identified within exosomes the results shown 
are expression relative to the first time point for each miRNA. 
2.11 Data Analysis   
Data were analysed using GraphPad Prism 6. Graphs were plotted  SD or  SEM as 
appropriate as specified in figure legends.  
 
3 Results 
3.1 CSF of preterm infants with PHH contains exosomes 
 
Nanoparticle tracking analysis (NTA) is a widely used technique in the EV field to 
accurately determine the size distribution and concentration of nanoparticles in 
Figure 1 A) Nanoparticle tracking analysis of CSF from three patients with PHH. 120-
second videos were recorded for each patient and concentrations taken as an average of 
triplicate runs. Lines show the concentration of particles at a given size within whole CSF  
SEM.  Data is processed with the finite track length adjustment algorithm on the NanoSight 
NS300 software. B) Concentration of particles detected in whole CSF, quantified using 
NTA. The shaded region of the bar indicates the concentration of particles within 30-
100nm range out of all particles detected.  
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fluids, based on the principle of Brownian motion24.  We performed NTA on CSF from 
three patient samples to determine whether nanoparticles the size of exosomes (30-
100nm) were present. Figure 1 (A) demonstrates there is a heterogeneous population 
of particles within CSF, and that this varies between patients. The mean particle size 
was 106.90.44nm, 156.92.08nm, and 120.771.2nm for patients 1, 2, and 3 
respectively. The modal particle sizes for patients 1 and 3 were similar: 86.2nm and 
81.9nm while the modal particle size in patient 2 was 159.3nm. Different particle 
concentrations were observed across the three patients: 2.89x10109.17x108; 1.13 x 
10113x109 and 3.47x10106.96x108particles/ml for patients 1, 2, and 3 respectively. 
The concentration of particles that fit the size criteria for exosomes was similar 
across all three patients: 1.53x10105.83x108; 1.59x10105.29x108 and 
1.48x10105.15x108particles/ml were within 30-100nm for patients 1, 2 and 3 
respectively. It is likely that this represents a low estimate for small-EV concentration 
as, due to the limits of refraction, this analysis under-samples small vesicles (<45nm). 
Interestingly, although CSF from patient 2 contained the highest total concentration 
of particles, only 14.1% was within the exosomal range compared to 53% and 42.5% 
in patient 1 and patient 3 respectively (Figure 1 (B)).  
3.2 CSF particle profiling over the course of four months following PHH 
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Figure 2 A) Nanoparticle tracking analysis of CSF nanoparticles from patient 3 over the 
course of four months. 120-second videos were recorded for each sample and concentrations 
taken as an average of triplicate runs. Lines show the concentration of particles at a given size 
within whole CSF  SEM.  Data is processed with the finite track length adjustment algorithm 
on the NanoSight NS300 software. B) Concentration of particles detected in whole CSF, 
quantified using NTA over the course of four months. The shaded region of the bar indicates 
the concentration of particles within 30-100nm range out of all particles detected. C) 
Regression analysis showing positive correlation between days post PHH and mean 
extracellular vesicle size in CSF.  
 
 
To further this characterisation, we focused on patient 3 as CSF samples were 
obtained throughout the treatment course. NTA of whole CSF taken at five time points 
revealed the heterogeneous population of EVs within CSF (Figure 2 (A)). Exosome-
sized particles were detected in all samples of CSF. At 25, 32 and 54 days old the 
modal particle sizes were within the range of exosomes (83.6nm, 81.9nm and 85.4nm 
respectively). At 29 and 124 days the modal particle size was above the size criteria 
for exosomes (104.6, and 122.6nm respectively). The mean particle sizes were 
113.601.70nm, 132.401.82nm, 120.771.82nm, 119.33.24nm, 135.250.55nm, 
and 162.601.57nm for 25, 29, 32, 54, and 124 days. Interestingly, both the overall 
particle concentration and the proportion of particles within 30-100nm range appear 
to show a gradual decrease with the GMH-IVH treatment progression (Figure 2 (B)).  
While the mean (R2=0.801, p=0.016) and modal (R2=0.744, p=0.027) particle size 
increases with time following PHH (Figure 2 (C)). AC
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3.3 CD63+ and CD81+ exosomes are present in the CSF of premature infants 
following PHH 
NTA cannot distinguish between EVs and similar sized particles which lack a lipid 
membrane, therefore we used TEM to qualitatively characterize these vesicles. We 
compared three isolation methods. Differential ultracentrifugation is the original 
protocol used to isolate exosomes, described by Raposo et al., 199625.  
Ultracentrifugation followed by a washing step is suggested by Théry et al (2006)21 as 
a means of removing contaminating proteins, although it has been reported to result 
in a reduced exosomal yield26. The commercially available exoEasy Maxi Kit isolates 
EVs using a spin-column system whereby EVs bind to an affinity membrane based on 
the presence of vesicular biochemical features. Exosome purification using this kit 
takes under 30min. Following exosome isolation, the final eluates were negatively 
stained for TEM. EVs were observed under electron microscopy in all three patients 
with all purification methods. These had the characteristical spherical shape with a 
lipid bilayer and corresponded to the size of exosomes (30-100nm) (Figure 3 (A-C)). 
Of note, following isolation via the exoEasy kit, the final eluate appeared cloudy and 
large precipitates were observed under electron microscopy (Figure S2). 
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CD63 and CD81 are surface tetraspanins widely used as markers for exosomes 27. 
Following exosomal isolation of CSF, we stained the exosome-enriched fraction using 
immunogold labelling techniques and anti-CD63/anti-CD81 antibodies. Colloidal gold 
particles, shown as small black dots in Figure 3 (H-I) indicated positive labelling for 
both tetraspanins on the surface of nanoparticles within the size range and 
morphology of exosomes. To determine the size distribution of EVs isolated from the 
CSF, imaged electron micrographs were viewed in ImageJ and EVs manually counted. 
A total of 265 EVs were counted across the 3 patients, which ranged from 23.1nm to 
214.9nm in diameter. For patients 1-3, the modal particle sizes were 42.5nm 
(x ̅=53.523.8nm), 42.5nm (x ̅=75.539.2nm) and 32.5nm (x̅=42.118.5nm) 
respectively (Figure S3). All modal particle sizes were within 30-100nm suggesting 
Figure 3: Transmission electron micrographs of extracellular vesicles isolated from the 
CSF of three patients following differential ultracentrifugation. Samples were negatively 
stained with uranyl acetate. A-C (patients 1-3 respectively) show cup-shaped membranous 
vesicles within the size range of exosomes, indicated by white arrowheads. Insets (D-G) 
show zoomed in area of probable exosomes. H and I show positive immunogold labelling 
for CD63 and CD81 (6nm gold particles) from patient 3. CSF samples were aspirated from 
the patient at 75 days old. White scale bars indicate 100nm, black scale bars 20nm. 
 
CC
EP
TE
D M
AN
US
CR
IPT
Spaull et al., 2018 
 15  
that the majority of nanoparticles purified following exosome isolation are within the 
size range of exosomes. As expected, larger particles are removed by the 10,000 g 
spin and therefore both modal and mean particle sizes following purification were 
lower than the original values obtained with NTA.  
3.4 The exosome-enriched fraction of CSF contains miRNA 
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After demonstrating the presence of exosomes in CSF, based on morphology, size and 
positive immunogold labelling, we aimed to isolate exosomal RNA. Following 
exosome isolation, total RNA was extracted from all samples. Ultracentrifugation and 
ultracentrifugation with a washing step yielded similar levels of RNA at 
0.20.004ng/μl and 0.160.042ng/μl respectively. Exosome isolation using the 
exoEasy kit yielded the most RNA at 0.470.324ng/μl, but final RNA concentrations 
were remarkably variable (Figure S4). To determine whether exosomal miRNAs are 
present in the CSF of patients with infantile PHH, five miRNAs (previously shown to 
be present in CSF/serum23) were selected and quantified by qPCR. These miRNAs 
were miR-17 (serum-specific), miR-26a (highly expressed in CSF exosomes), miR-124 
(brain-specific), miR-9 (brain specific and known regulator of neurogenesis28) and 
miR-1911 (brain specific, highly enriched in CSF exosomes). Mature miRNA 
sequences are detailed on Figure 4 (A). All five miRNAs were detectable in the 
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exosome-enriched fraction of CSF. miR-9 and miR-26a levels were relatively constant 
over the course of four months following PHH. Interestingly, we observed a decrease 
in expression levels of miR-17 and miR-124 at the latest time point (124 days after 
birth) relative to the earliest time point (25 days after birth). Conversely miR-1911 
expression showed a general increase over the four months following PHH (Figure 4 
(B)).  
Figure 4:  A) Mature miRNA sequences, miR-base ID and tissue expression for each of the 
RNA selected for this study. E: RNA detected in exosomes, S: RNA detected in cell 
supernatant.  B) Relative expression of five miRNAs over four months quantified using 
qPCR. CSF samples from patient 3 was ultracentrifuged at 100,000 g (section 3.3.1). RNA 
was isolated from the exosome-enriched pellet using the mirVana™ miRNA Isolation Kit 
and reverse transcription and qPCR performed using the TaqMan® MicroRNA Assay.  
Expression of each miRNA was normalised to the starting volume of CSF and relative to the 
earliest CSF acquisition time point. 
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4 Discussion 
Our first aim was to confirm the presence of exosomes in the CSF of our patient 
cohort, as exosomes had been previously documented in human adult CSF29.  Our 
NTA data of whole PHH-CSF suggested the presence of exosomes, apoptotic 
bodies, and microvesicles in all samples for all three of our patients. The 
concentration of EVs in CSF is an order of magnitude lower than in the serum, 
with typical concentrations of 1.1x1010 particles/mL29. We then profiled the 
concentrations of each patient sample and the relative number of particles 
within the exosomal range. Patient 2 had a much higher particle concentration 
and contained a larger proportion of particles >100nm compared to patients 1 
and 3, suggesting a higher concentration of microvesicles or apoptotic bodies in 
this patient. Interestingly, Georgiadis et al. 2008 reported an inflammatory 
response in a rabbit model of GMH-IVH with an increased number of apoptotic 
cells in the periventricular zone of the brain compared to a control group 
without GMH-IVH30. Therefore, a larger proportion of apoptotic bodies in patient 
2 could indicate a greater ongoing inflammatory response. However, whether 
the number of apoptotic bodies present in PHH-CSF impacts the future prognosis 
in these patients remains to be investigated.  
Following the confirmation that exosome-sized nanoparticles were present in 
PHH-CSF, we sought to further characterise them using TEM since NTA cannot 
distinguish between exosomes and similarly sized particles which lack a 
membrane. TEM revealed spherical vesicles with a continuous membrane that 
were CD63+ and CD81+ supporting the presence of exosomes in PHH-CSF. 
However, it is important to keep in mind that one of the primary limitations in 
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the exosome field is the lack of a definitive marker and that none of the reported 
proteins (including CD63 and CD81) are completely exclusive to exosomes. TEM 
quantification also demonstrated that there is a heterogeneous population of 
nanoparticles in PHH-CSF even after exosome isolation. This heterogeneity is in 
agreement with Willms et al., 2016 who demonstrated the presence of two 
distinct exosome subpopulations within the culture media of 4 different cell 
types. These subpopulations had different modal sizes, protein content, RNA 
composition and different functional effects on recipient cells31. We then profiled 
nanoparticle composition over a four-month time period following PHH. NTA 
revealed a general decrease in the concentration of exosome-sized nanoparticles 
over the course of four months following PHH. Interestingly Tietje et al., 2014 
have reported a similar temporal decline in the concentration of CSF EVs over 
the course of 85 years32 suggesting that this may be of biological significance.  
However, further investigation is needed to ascertain whether the decline in CSF 
particle concentration is specific to PHH, or occurs as a consequence of perinatal 
development.  
We then attempted to isolate exosomal RNA from our CSF samples. Following 
RNA isolation, we used qPCR to determine the presence of exosomal miRNAs. 
Due to the low yield of RNA and limited sample volumes, we focused on a small 
panel of miRNAs selected on the basis of their presence in CSF and serum 
fractions. miR-17, miR-26a, miR-124, miR-1911 and miR-9 were detectable in 
PHH-CSF albeit at low expression levels.  This is in line with the stoichiometric 
analysis of biofluid samples and in vitro cultures performed by Chevillet et al., 
that found only ~1 miRNA to every 121 exosomes33. We then hypothesised that 
exosomal miRNA expression might change over time following GMH-IVH, as 
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such, we performed qPCR on a panel of five miRNAs. miR-9 is an important 
regulator of neurogenesis, involved in coordinating both differentiation and 
proliferation of NSCs34,35. miR-26a has been shown to induce neurite outgrowth 
in rats; an essential process during neuronal migration and differentiation 
during development36. Expression of both miR-9 and miR-26a remained 
constant over the four months following PHH. This was unexpected considering 
their implications in neuronal development but suggest that they would not be 
suitable biomarkers for GMH-IVH progression. miR-17 is a serum-specific 
miRNA23. We observed a negative correlation between miR-17 and time 
following PHH. Disruption of the blood brain barrier (BBB) and/or direct 
bleeding at the time of injury in GMH-IVH, leads to serum contamination and 
therefore abnormal expression of miR-17 in early CSF samples. A progressive 
reduction of miR-17 CSF levels could reflect restoration of the BBB integrity. 
miR-124 is a highly conserved and abundantly expressed, brain-specific 
miRNA37. miR-124 expression has been shown to increase during neuronal 
development in line with maturation of neurons in a rat model38. However, in 
our cohort mir-124 expression was negatively correlated with time following 
PHH which could underpin some of the developmental impairment seen in GMH-
IVH patients. miR-1991 was selected as a brain-specific miRNA, found to be 
highly enriched in CSF exosomes. The increase in miR-1911-5p following GMH-
IVH and the development of PHH make this an interesting potential biomarker.  
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5 Conclusions 
To our knowledge, this is the first evidence of exosomes and exosomal miRNA 
expression in PHH-CSF. We have demonstrated the presence of a heterogeneous 
population of EVs in PHH-CSF which includes CD63+ and CD81+ exosomes. We 
have shown that the exosomal concentration decreases over the course of four 
months following PHH and that these exosomes contain miRNA that may present 
themselves as potential biomarkers for PHH.  These miRNAs are critical for brain 
development and therefore may reflect patient responses to treatments or the 
pathological processes occurring in the development or resolution of PHH.  
 
None of the participating scientists have competing financial interests. 
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